Pupil size affects coma value in certain eyes

Article

When compared with eyes of normal axial length, high-myopic pseudophakic eyes with posterior staphyloma had significantly less internal coma and less coma variations during mydriasis, according to recently published research.

When compared with eyes of normal axial length, high-myopic pseudophakic eyes with posterior staphyloma had significantly less internal coma and less coma variations during mydriasis, according to research published in Eye.

The researchers studied 60 eyes: 40 in highly myopic cataract patients with posterior staphyloma and 20 in cataract patients with normal axial length.

They found that the high-myopic pseudophakic eyes with posterior staphyloma had significantly lower values of internal coma - both under 4 mm and 6 mm pupil sizes - at 1 month after phacoemulsification and IOL implantation compared to eyes with normal axial length.

The high-myopic pseudophakic eyes with posterior staphyloma also had significantly lower internal total higher-order aberrations and third-order aberrations at 6-mm pupil size.

In addition, the researchers found statistically significant differences between the two groups in the variation from 4- to 6-mm pupil sizes for:

  • internal coma
  • internal third-order aberrations

  • internal total higher-order aberrations
  • ocular coma aberrations.

Strehl ratio increased significantly in high-myopic eyes and decreased slightly in normal axial length eyes after mydriasis, and modular transfer functions were found to vary in a statistically significant manner between the two groups at frequencies of 15, 30, 45 and 60 cycles/degree.

To read an abstract of the study, click here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.